Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

353 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Economic evaluation of multiple sclerosis in the UK, Germany and France.
Murphy N, Confavreux C, Haas J, König N, Roullet E, Sailer M, Swash M, Young C, Mérot JL; Cost of Multiple Sclerosis Study Group. Murphy N, et al. Among authors: confavreux c. Pharmacoeconomics. 1998 May;13(5 Pt 2):607-22. doi: 10.2165/00019053-199813050-00013. Pharmacoeconomics. 1998. PMID: 17165327
Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis.
Brochet B, Guinot P, Orgogozo JM, Confavreux C, Rumbach L, Lavergne V. Brochet B, et al. Among authors: confavreux c. J Neurol Neurosurg Psychiatry. 1995 Mar;58(3):360-2. doi: 10.1136/jnnp.58.3.360. J Neurol Neurosurg Psychiatry. 1995. PMID: 7897422 Free PMC article. Clinical Trial.
Natural history of multiple sclerosis with childhood onset.
Renoux C, Vukusic S, Mikaeloff Y, Edan G, Clanet M, Dubois B, Debouverie M, Brochet B, Lebrun-Frenay C, Pelletier J, Moreau T, Lubetzki C, Vermersch P, Roullet E, Magy L, Tardieu M, Suissa S, Confavreux C; Adult Neurology Departments KIDMUS Study Group. Renoux C, et al. Among authors: confavreux c. N Engl J Med. 2007 Jun 21;356(25):2603-13. doi: 10.1056/NEJMoa067597. N Engl J Med. 2007. PMID: 17582070 Free article.
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity.
Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, le Page E, Edan G, McDonnell GV, Hawkins S, Trojano M, Liguori M, Cocco E, Marrosu MG, Tesser F, Leone MA, Weber A, Zipp F, Miterski B, Epplen JT, Oturai A, Sørensen PS, Celius EG, Lara NT, Montalban X, Villoslada P, Silva AM, Marta M, Leite I, Dubois B, Rubio J, Butzkueven H, Kilpatrick T, Mycko MP, Selmaj KW, Rio ME, Sá M, Salemi G, Savettieri G, Hillert J, Compston DA. Roxburgh RH, et al. Among authors: confavreux c. Neurology. 2005 Apr 12;64(7):1144-51. doi: 10.1212/01.WNL.0000156155.19270.F8. Neurology. 2005. PMID: 15824338
A 10-year follow-up of the European multicenter trial of interferon β-1b in secondary-progressive multiple sclerosis.
Kuhle J, Hardmeier M, Disanto G, Gugleta K, Ecsedi M, Lienert C, Amato MP, Baum K, Buttmann M, Bayas A, Brassat D, Brochet B, Confavreux C, Edan G, Färkkilä M, Fredrikson S, Frontoni M, D'Hooghe M, Hutchinson M, De Keyser J, Kieseier BC, Kümpfel T, Rio J, Polman C, Roullet E, Stolz C, Vass K, Wandinger KP, Kappos L; European Long-term Follow-up Study Group in Interferon β-1b in Secondary-progressive Multiple Sclerosis. Kuhle J, et al. Among authors: confavreux c. Mult Scler. 2016 Apr;22(4):533-43. doi: 10.1177/1352458515594440. Epub 2015 Sep 11. Mult Scler. 2016. PMID: 26362898 Clinical Trial.
353 results